226 related articles for article (PubMed ID: 8259386)
1. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Newman JS; Francis IR; Kaminski MS; Wahl RL
Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
[TBL] [Abstract][Full Text] [Related]
2. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.
Tatsumi M; Cohade C; Nakamoto Y; Fishman EK; Wahl RL
Radiology; 2005 Dec; 237(3):1038-45. PubMed ID: 16304117
[TBL] [Abstract][Full Text] [Related]
6. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
[TBL] [Abstract][Full Text] [Related]
7. The impact of FDG positron emission tomography imaging on the management of lymphomas.
Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
[TBL] [Abstract][Full Text] [Related]
8. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
[TBL] [Abstract][Full Text] [Related]
9. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
[TBL] [Abstract][Full Text] [Related]
10. Extranodal malignant lymphoma: detection with FDG PET versus CT.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Merkle E; Frickhofen N; Reske SN
Radiology; 1998 Feb; 206(2):475-81. PubMed ID: 9457202
[TBL] [Abstract][Full Text] [Related]
11. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
[TBL] [Abstract][Full Text] [Related]
12. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
[TBL] [Abstract][Full Text] [Related]
13. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
14. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.
Allen-Auerbach M; Quon A; Weber WA; Obrzut S; Crawford T; Silverman DH; Ratib O; Phelps ME; Czernin J
Mol Imaging Biol; 2004; 6(6):411-6. PubMed ID: 15564152
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Ann Nucl Med; 2015 Feb; 29(2):132-7. PubMed ID: 25348549
[TBL] [Abstract][Full Text] [Related]
16. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
[TBL] [Abstract][Full Text] [Related]
17. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.
Wahl RL; Quint LE; Greenough RL; Meyer CR; White RI; Orringer MB
Radiology; 1994 May; 191(2):371-7. PubMed ID: 8153308
[TBL] [Abstract][Full Text] [Related]
18. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.
Stumpe KD; Urbinelli M; Steinert HC; Glanzmann C; Buck A; von Schulthess GK
Eur J Nucl Med; 1998 Jul; 25(7):721-8. PubMed ID: 9662594
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses.
Anzai Y; Carroll WR; Quint DJ; Bradford CR; Minoshima S; Wolf GT; Wahl RL
Radiology; 1996 Jul; 200(1):135-41. PubMed ID: 8657901
[TBL] [Abstract][Full Text] [Related]
20. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA
Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
